Valentina Tateo

Sep 6, 2024 | brnw.ch | Marco Moschini |Antonio Cigliola |Valentina Tateo

Data Sharing StatementData Sharing StatementData SupplementAuthors retain all rights in any data supplements associated with their articlesThe ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.

Dec 11, 2023 | europeanurology.com | Antonio Cigliola |Valentina Tateo |Carlo Bosi |Alberto Briganti

Vale CL, Fisher DJ, Godolphin PJ, et al. Lancet Oncol 2023;24:783–97The meta-analysis by Vale and colleagues reports the effects of docetaxel added to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) according to patient characteristics. The authors proved that docetaxel prolongs overall survival (OS) in patients with poorer prognosis (high-volume [HV] disease and “bulky” T4 stage tumor).

Apr 19, 2023 | mdpi.com | Paola Valeria Marchese |Veronica Mollica |Francesco Massari |Valentina Tateo

1. Introduction 1.1. Brief History of a Therapeutic Paradigm Change: The Revolution in OncologyAt the dawn of oncology, between the end of 1800 and the beginning of 1900, just a few Cancer Centers existed worldwide, and treatments consisted of surgery, x-rays, and the very first chemotherapeutic agents. Then, the decades of chemotherapy boom arrived, from 1940 to 1970, with a great expansion of available chemotherapeutic agents and combination schemes.